Fundz

Who to call at Exscientia, and when

Fundz watches for the moments Exscientia starts buying, and tells you who to reach.

  • An alert the day Exscientia raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Exscientia, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Recursion and Exscientia Enter Definitive Agreement to Combine Forces in Drug Discovery

Aug 08, 2024

Contract Type

agreement

OxfordBiotechnologySoftwareData And AnalyticsHealth CareScience And EngineeringArtificial Intelligence

Description

Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have entered into a definitive agreement to combine forces, aiming to industrialize drug discovery, deliver high-quality medicines, and lower prices for consumers. The agreement aims to bring together their respective expertise and capabilities in technology-enabled biology, chemistry exploration, precision oncology, rare disease, and infectious disease treatments.

Company Information

Company

Exscientia

Location

Oxford, Mississippi, United States

About

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Predictive Intelligence
Strategic

ML-powered predictions for Exscientia's next move

Learn about Strategic plan

Exscientia signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.